SBFM - Sunshine Biopharma Doing BIG Things!Always DYOR and understand the dynamics of these OTC stocks (known for pump & dump) but the fundamentals here are what will ultimately drive Sunshine Biopharma to return to it's formerly glorious highs but for now, it's relegated to the fractional levels that we see. On it's face, it looks like a no-brainer . . company shedding debt, increasing earnings (still no real profitability) BUT, a recent patent publication and a litany of amazing solutions in the areas of drug-resistant cancers, COVID-19, etc. But don't take my word for it . . check it out . .
sunshinebiopharma.com
Caveat Emptor - The evil corporate empire will probably try to keep this one squashed and on the DL with massive shorting (if I had to guess) and for several reasons
1. Competition
2. Cancer is big business and people that cure it tend to go away quickly
3. Keep the price low with the help of WS peckerwoods for a cheaper acquisition
Again, I don't render professional investment advice, I just read charts and try to tie the fundamentals into a more complete picture. The Fib channel looks attractive in an uptrend, we just got a nice bump up above the 50/200 EMA and we know what kind of price history this beauty has so it's worth an add. I've got a DCA bag and will LTBH it for either a buyout or until the WS woods drive it to zero, whatever the outcome . . no risk, no reward.
Good luck!
Coronavirusstocks
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap 27.124Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
OCGN COVAXIN Robust Immune Memory to COVID-19 and VariantsNew Data suggest COVAXIN (BBV152) may provide protection against current and future variants!
data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.
52 Week Range 0.28 - 18.77
My price target is the 10.30usd resistance.
Omicron Weighs on Global StocksWe cautioned readers yesterday to exercise caution with stocks and this advice was warranted, as stocks have dipped further into negative territory. Global stocks have pushed lower with news of the first case of the Omicron strain of the Coronavirus was confirmed in the United States. We have broken through what appeared to be strong support at 4580, then 4564, taking out several levels below, and finally finding support at 4504, confirmed by a green triangle on the KRI. All of these levels we have discussed in the past, and we gave comments to yesterday's report keeping readers updated. The Kovach OBV is quite bearish, but we are currently seeing another meager attempt at a rally, which is currently facing resistance confirmed by a red triangle on the KRI at 4545, another one of our levels. From here it depends on how the markets will interpret this news further. A rally will have to break 4580 and cross the vacuum zone above for stocks to attempt a recovery. Further fallout could break 4504 and test the 4400's, with 4487 and 4462 being the next targets. We still advise caution in buying this dip as the fallout may persist, or we may see at least some volatility as markets jostle for footing.
$BNTX^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Moderna up again!Hi guys, I think Moderna will go up again and get a trend change up. Today Moderna breaks out of the trenchannel and the rsi has also potential for going up. If the chart goes over the EMAs than it get also from them supported and have a good chance to go up again.
what you guys think?
CEMI Chembio Diagnostics Earnings August 5thTomorrow Chembio Diagnostics CEMI will Report Second Quarter 2021 Financial Results.
Things to consider:
$28.3 million purchase order from Bio-Manguinhos for SARS-CoV-2 Antigen tests in Brazil
$4 million purchase order from the Partnership for Supply Chain Management (PFSCM), for the purchase of HIV 1/2 STAT-PAK Assay for shipment to Ethiopia
those are just some big orders from July, Q3, for which we could se a business update tomorrow at the earnings call.
Craig Hallum has a $10.00 price target for it.
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO
But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday?
Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19."
"we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001."
"NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months."
Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases.
The Market Cap if only 88.473Mil at the time or writing!
In search for the next BNTX, MRNA and NVAX !!Since Covid-19 is here to stay with us with its variants and the vaccines don`t offer lifetime protection, this means that there is room for other companies to develop a better vaccine to address the problem.
And the gains in vaccines stock are quite similar to cryptocurrencies year over year.
From all time low to all time high, BNTX made 19X, MRNA 24X and NVAX 66X.
My question for you is the following: which is the next vaccine developer to make at least 10X our money?? I`m looking forward to discover with you the next big vaccine developer!
And i have a presumption or two which i already shared in my group. And those were the fundamentals i was searching for: data submitted to FDA for Emergency Use Authorization, Phase 3, low Market cap - under 1Bil, on the lower end of 52 Week Range, other drugs in the pipeline, high intraday volume.
NVAX Novavax Analyst RatingsOn 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00
On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00
On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00
On 5/12/2021 HC Wainwright brokerage Lowered the Price Target from $317.00 to $294.00
My personal price target is $240.
Looking forward to read your opinion.
VXRT Vaxart Covid-19, Uptrend and Price TargetVXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection.
A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates.
On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies in trial participants, which makes it less efficient than traditional COVID-19 injections.
On 6/11/2021 Piper Sandler brokerage Initiated Coverage with Overweight rating and a Price Target of $18.00
From a technical analysis point of view, the stock looks in an uptrend.
Borussia Dortmund (BVB) to break out of corona struggles 🏆BVB is undervalued anyway and hasn't fully bounced back from the corona virus hit yet - great upward potential 🏆
As one of the few european football stocks out there, Borussia Dortmund is a rare opportunity from both fundamental perspective and in regards to the corona pandemic, which naturally damaged this stock substantially. But it's time to bounce back!
With a market cap of about €500m, the stock is undervalued anyways and was on it's way to a fair price before corona hit. The player value alone is estimated to be more than €500m, not to mention the entire infrastructure and brand. Borussia Dortmund is probably the most renouned German football club after Bayern Munich and successfully toured to North America and Asia to tap into new markets. Just before corona, the club approached one billion euros in value - and since then, not much has really changed.
Empty stadiums have hurt the club and cost about €2-3m each game which explains the moderate losses reported in recent quarterly reports. But with the great progress of the German vaccination campaign and established concepts that were tested in the beginning of the pandemic, which allowed at least parts of the stadium to be filled with fans, we can savely assume a return to "normal" games and stadium capacity with the next Bundesliga season in August.
Borussia Dortmund is famous for great talent management and player transfers. The two most valued Bundesliga players belong to Borussia Dortmund - Haaland and Sancho - and while a sale of either or both players would not be favoured by fans and could impact the team's performance for a short while, it would do wonders for the balance sheet. Other young players like Moukoko and Bellingham, 17 and 16 years old respectively, haven't even taken off yet and will bring either great quality to the team, resulting in titles and price money, or can be sold at a massive profit in the next years.
To sum it up: The club has suffered from the coronavirus crisis and hasn't fully bounced back yet. The market cap is below the team's value alone with the brand intact and a great long-term outlook. Short-term, the team is on the verge on collecting a national cup title and securing a spot in next year's UEFA champions league.
Humanigen ($HGEN) with a lot of potentialThe COVID-19 pandemic is holding the world, the economy and our health in a tight grip. So far Biontech/Pfizer have been successful with their vaccination, but as the virus mutates, it is unclear how effective the vaccination is. Many COVID-19 infected patients have to be hospitalized with a need for mechanical ventilation and that is where Humanigen plays a major role.
Humanigen reports positive Phase 3 topline results demonstrating that their drug under the name Lenzilumab™ improves survival without need for mechanical ventilation. These news are really huge and better yet: Humanigen has requested an Emergency-Use-Authorization (EUA) from the FDA.
Now looking at the price development of the share, there were some nice intraday profit taking (PT) opportunities, but the stock has actually a potential to grow much more.
Look at the trading range and monthly levels to set your PT levels. There was a nice retest of the support level (at 15$ and a bit below), which had provided and excellent opportunity to buy in cheap, but catching a falling knife takes a lot of practice (I rarely succeed myself, but I was lucky with this particular trade).
Have your PT goal in mind, because most of the times people lose money, because they become to greedy or don't cut losses (had to learn this the hard way myself :D).
Other than that, I am really optimistic on the upwards potential of this gem.
- This is no financial advice, so trade with care -
For transparency: I am invested in $HGEN with 1/3 of my stock portfolio and usually keep 2/3 for dollar cost averaging.
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
$NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application.
NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform.
$NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2.
Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below.
NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates.
The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA.
The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses.
finance.yahoo.com
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients
The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.
finance.yahoo.com
$IMNM Discovers Antibodies Capable of Neutralizing SARS-CoV-2Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
finance.yahoo.com
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February
There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media.
$IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month.
iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores.
The company generates a majority of its revenue from its retail segment.
The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19.
www.benzinga.com
twitter.com
OCGN - how to play the COVAXIN news !OCGN:
What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative.
Ok lets talk shop – technical:
POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason.
Volume: average volume is 63M, last 2 days trading above 100M.
50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal)
4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions….
Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal.
The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high
Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+.
Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !!
FDGT will wait for a pullback before entering as the trend doesn’t look healthy
This is not a recommendation of any sort
Trader safe and be safe – we are the traders union and we trade by our own rules!
Potential Development of an Oral COVID-19l VaccineAeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases, including COVID-19.
- Aeterna Zentaris to evaluate the University’s coronavirus vaccine platform technology including COVID-19 under an exclusive option agreement.
to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities.
The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.
Under the option agreement entered into with the University, Aeterna has the right to negotiate an exclusive worldwide license to develop this technology for the prevention of coronavirus diseases, including COVID-19.
A scientific advice meeting with the German authorities at Paul-Ehrlich Institute has been scheduled by the University to discuss a roadmap towards initiating a first-in-human clinical trial.
finance.yahoo.com
Aeterna expects to make a decision whether to exercise its option to negotiate a license for that technology by mid 2021.
Abandon Ship! Time to short or sell that under performing CCL!Carnival is tanking fast and it's all hands on deck. All technical indicators say to sell and as trend traders; we trade the trend instead of going down with the ship!!
Corona(Covid 19 vaccine) stock that can explode in 2021A little-known biotech is trying its hand at developing a coronavirus vaccine. Can it succeed?
over the past year, Vaxart stock has soared over 1,250% because of its spot in the lucrative coronavirus vaccine race.
Its stock performance even outpaced those of biotechs that have already brought their coronavirus vaccines to market, such as Moderna and BioNTech.
In fact, over 30% of Vaxart stock has been sold short.
Vaxart claims to have created an experimental coronavirus vaccine in the form of an oral tablet. One could potentially self-administer the vaccine pill, which is stable at room temperature. This would allow patients to order the vaccine online and have it delivered for at-home use.
At the moment, Vaxart's experimental coronavirus vaccine is only in phase 1 clinical trials, with a new data readout expected by next week.
Unfortunately, it's impossible to conclude how the experimental vaccine will work on humans from animal models. Hence, the candidate's phase 1 data release will likely be a make-or-break moment for Vaxart.
Vaxart is under investigation by both the U.S. Securities and Exchange Commission (SEC) and the Department of Justice (DOJ) for insider trading and inaccurate statements regarding its role in Operation Warp Speed (OWS).
Even though Vaxart has more than $133 million in cash and equivalents with no debt whatsoever, that's not nearly enough to move forward. Right now, it could cost billions of dollars to run a potential coronavirus vaccine through clinical trials involving tens of thousands of participants. The company will likely sell more stock to pay for its research and development (R&D) expenses or apply for grant funding -- just to stay afloat.
Vaxart is far riskier than the other coronavirus vaccine drugmakers out there. Its corporate conduct is under federal investigation, and its vaccine candidate is in far too early a stage to draw any definitive conclusions about.
With a market cap just south of $1 billion, it will undoubtedly become a very undervalued stock if it can bring a coronavirus vaccine to market. Moderna, which has done so, projects $11.7 billion in revenue from its mRNA-1273 vaccine alone. However, the probability of Vaxart achieving anything remotely similar is up for debate.
Short-sellers and passionate bulls will be arguing over the stock for the next year. If you believe in Vaxart's science and have the stomach for a roller-coaster ride, then go for it.
HelloFresh: profitable growth stock with a reasonable valuationHelloFresh is a multinational German company that delivers home, packaged in a box, the fresh ingredients of its recipes selected online
by the customer to cook them in their kitchen in half an hour.
HelloFresh operates in Germany, USA, Australia, Austria, Belgium, Canada, the Netherlands, Switzerland, and the United Kingdom.
Its anyway strong growth accelerated in 2020 due to CORONAVIRUS. Regarding its profitability, we do not just hope that the company
will likely become profitable sometime, it is already profitable, and its valuation is very reasonable given its growth.
Below are presented the mid- and short-term trend charts of HelloFresh.
Disclaimer
The writer of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only. It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances, it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
